Ashland (ASH) executive compensation, 2025 proxy

Guillermo Novo, Chair and Chief Executive Officer, was paid $7.9M in 2025, down 12% from $9M the year before. The CEO-to-median-employee pay ratio was 83:1, on median employee pay of $95,293.

Filed
December 9, 2025
Annual meeting
January 20, 2026
Pay year
2025
Named executives
7
CEO total pay
$7.9M-12% vs prior year
CEO to median employee
83:1median $95,293
CEO pay in equity
66%$5.2M in awards
CEO Target Bonus
$1,452,950Annual incentive plan target
CEO Stock Awards
$5,233,863Grant date fair value
Stock Repurchased
$100 million1.5 million shares repurchased
Adjusted EBITDA
$401 millionNon-GAAP measure

How Novo was paid

$7.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary15%Stock awards66%Non-equity incentive17%All other compensation3%

Named executive officers

ExecutiveTotal
Guillermo NovoChair and Chief Executive Officer$7,907,423
William WhitakerSVP and Chief Financial Officer$2,350,368
Alessandra Faccin AssisSVP & GM Life Sciences & Intermediates$2,086,178
Osama M. MusaSVP, Chief Technology Officer$1,743,822
James P. MinicucciSVP & GM Personal Care$1,421,501
Karl BostaphSVP, Operations$1,536,524
J. Kevin WillisSVP, Chief Financial Officer$2,407,328

What changed and why

  • $7.9MChief executive officer total compensation decreased to $7,907,423 in fiscal 2025.
  • $5.2MStock awards for the chief executive officer decreased to $5,233,863 compared to the prior year.
  • $1.3MNon-equity incentive plan compensation for the chief executive officer decreased to $1,313,830.
  • Named executive officers achieved zero percent of target performance under the 2023-2025 long-term incentive program.
  • The chief executive officer to median employee pay ratio was reported as 83 to 1.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.